➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Merck
Colorcon
McKesson
Johnson and Johnson

Last Updated: June 16, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for SGI-1776


Email this page to a colleague

« Back to Dashboard

What is the drug development status for SGI-1776?

SGI-1776 is an investigational drug.

There have been 27 clinical trials for SGI-1776. The most recent clinical trial was a Phase 2 trial, which was initiated on February 1st 2017.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, and Leukemia, Myeloid. The leading clinical trial sponsors are Astex Pharmaceuticals, National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are thirty-eight US patents protecting this investigational drug and two hundred and seventy-two international patents.

Recent Clinical Trials for SGI-1776
TitleSponsorPhase
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaNational Cancer Institute (NCI)Phase 2
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerAstex PharmaceuticalsPhase 1/Phase 2
Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal CancerBristol-Myers SquibbPhase 1/Phase 2

See all SGI-1776 clinical trials

Clinical Trial Summary for SGI-1776

Top disease conditions for SGI-1776
Top clinical trial sponsors for SGI-1776

See all SGI-1776 clinical trials

US Patents for SGI-1776

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
SGI-1776   Get Started Free Bicyclic fused pyrimidine compounds as TAM inhibitors Incyte Corporation (Wilmington, DE)   Get Started Free
SGI-1776   Get Started Free Pyrrolopyrimidine derivatives as TAM inhibitors Incyte Corporation (Wilmington, DE)   Get Started Free
SGI-1776   Get Started Free Compositions and methods for treating cancer with JAK2 activity DUKE UNIVERSITY (Durham, NC)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for SGI-1776

Drugname Country Document Number Estimated Expiration Related US Patent
SGI-1776 World Intellectual Property Organization (WIPO) WO2017027717 2035-08-12   Get Started Free
SGI-1776 World Intellectual Property Organization (WIPO) WO2017035366 2035-08-26   Get Started Free
SGI-1776 World Intellectual Property Organization (WIPO) WO2015051252 2033-10-03   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Johnson and Johnson
McKesson
McKinsey
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.